Open Access

Overexpression of CKS2 is associated with a poor prognosis and promotes cell proliferation and invasion in breast cancer

  • Authors:
    • Naiqi Huang
    • Zuli Wu
    • Hong Hong
    • Xiangming Wang
    • Fengqiang Yang
    • Hengguo Li
  • View Affiliations

  • Published online on: April 5, 2019     https://doi.org/10.3892/mmr.2019.10134
  • Pages: 4761-4769
  • Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Growing evidence indicates that cyclin dependent kinases regulatory subunit 2 (CKS2) serves an essential role in the regulation of multiple cellular processes in diverse human cancer types. The present study investigated the contribution of CKS2 to breast cancer (BC) progression. In the present study, CKS2 expression in BC was detected using Oncomine and The Cancer Genome Atlas database. The association between expression levels and clinical features was explored using Kaplan‑Meier plotter and the Breast Cancer Gene‑Expression Miner Version 4.0 (bc‑GenExMiner) online database. In addition, the roles of CKS2 in BC progression were examined. It was identified that CKS2 expression was significantly increased in BC tissues at the mRNA and protein levels. Bc‑GenExMiner demonstrated that high CKS2 expression was associated with a positive estrogen receptor status, progesterone receptor status, nodal status and basal‑like status. High CKS2 expression was markedly associated with poor overall survival, relapse‑free survival, and distant metastasis‑free survival in patients with BC. Moreover, functional assays revealed that CKS2 inhibition suppressed cell proliferation and invasion ability in vitro and reduced tumor growth in vivo. Thus, the present findings suggested that CKS2 may act as a potential biomarker and therapeutic target for the treatment of BC.

References

1 

Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Tao Z, Shi A, Lu C, Song T, Zhang Z and Zhao J: Breast cancer: Epidemiology and etiology. Cell Biochem Biophys. 72:333–338. 2015. View Article : Google Scholar : PubMed/NCBI

3 

DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA and Jemal A: Breast cancer statistics, 2015: Convergence of incidence rates between black and white women. CA Cancer J Clin. 66:31–42. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Qian C, Guan M, Si C, Shen H, Jin T and Zhang T: Identification of differentially expressed profiles of lncRNAs and mRNAs in ER-negative and HER-2 positive breast cancer. Arch Med Sci Civil Dis. 2:148–160. 2017.

5 

Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, et al: Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 375:1738–1748. 2016. View Article : Google Scholar : PubMed/NCBI

6 

You H, Lin H and Zhang Z: CKS2 in human cancers: Clinical roles and current perspectives. Mol Clin Oncol. 3:459–463. 2015. View Article : Google Scholar : PubMed/NCBI

7 

Liberal V, Martinsson-Ahlzén HS, Liberal J, Spruck CH, Widschwendter M, McGowan CH and Reed SI: Cyclin-dependent kinase subunit (Cks) 1 or Cks2 overexpression overrides the DNA damage response barrier triggered by activated oncoproteins. Proc Natl Acad Sci USA. 109:2754–2759. 2012. View Article : Google Scholar : PubMed/NCBI

8 

Litchfield DW: Protein kinase CK2: Structure, regulation and role in cellular decisions of life and death. Biochem J. 369:1–15. 2003. View Article : Google Scholar : PubMed/NCBI

9 

Martinsson-Ahlzén HS, Liberal V, Grünenfelder B, Chaves SR, Spruck CH and Reed SI: Cyclin-dependent kinase-associated proteins Cks1 and Cks2 are essential during early embryogenesis and for cell cycle progression in somatic cells. Mol Cell Biol. 28:5698–5709. 2008. View Article : Google Scholar : PubMed/NCBI

10 

Chen R, Feng C and Xu Y: Cyclin-dependent kinase-associated protein Cks2 is associated with bladder cancer progression. J Int Med Res. 39:533–540. 2011. View Article : Google Scholar : PubMed/NCBI

11 

Lin L, Fang Z, Lin H, You H, Wang J, Su Y, Wang F and Zhang ZY: Depletion of Cks1 and Cks2 expression compromises cell proliferation and enhance chemotherapy-induced apoptosis in HepG2 cells. Oncol Rep. 35:26–32. 2016. View Article : Google Scholar : PubMed/NCBI

12 

Wang J, Xu L, Liu Y, Chen J, Jiang H, Yang S and Tan H: Expression of cyclin kinase subunit 2 in human breast cancer and its prognostic significance. Int J Clin Exp Pathol. 7:8593–8601. 2014.PubMed/NCBI

13 

Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001. View Article : Google Scholar : PubMed/NCBI

14 

Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, Dunning MJ, Speed D, Lynch AG, Samarajiwa S, Yuan Y, et al: The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature. 486:346–352. 2012. View Article : Google Scholar : PubMed/NCBI

15 

Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, et al: Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 100:8418–8423. 2003. View Article : Google Scholar : PubMed/NCBI

16 

Pontén F, Jirström K and Uhlen M: The Human Protein Atlas-a tool for pathology. J Pathol. 216:387–393. 2008. View Article : Google Scholar : PubMed/NCBI

17 

Lu XF, Zeng D, Liang WQ, Chen CF, Sun SM and Lin HY: FoxM1 is a promising candidate target in the treatment of breast cancer. Oncotarget. 9:842–852. 2018. View Article : Google Scholar : PubMed/NCBI

18 

Jézéquel P, Frénel JS, Campion L, Guérin-Charbonnel C, Gouraud W, Ricolleau G and Campone M: bc-GenExMiner 3.0: New mining module computes breast cancer gene expression correlation analyses. Database (Oxford). 2013:bas0602013. View Article : Google Scholar : PubMed/NCBI

19 

Györffy B, Lanczky A, Eklund AC, Denkert C, Budczies J, Li Q and Szallasi Z: An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients. Breast Cancer Res Treat. 123:725–731. 2010. View Article : Google Scholar : PubMed/NCBI

20 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

21 

Malumbres M and Barbacid M: Mammalian cyclin-dependent kinases. Trends Biochem Sci. 30:630–641. 2005. View Article : Google Scholar : PubMed/NCBI

22 

Zhao H, Lu Z, Bauzon F, Fu H, Cui J, Locker J and Zhu L: p27T187A knockin identifies Skp2/Cks1 pocket inhibitors for advanced prostate cancer. Oncogene. 36:60–70. 2017. View Article : Google Scholar : PubMed/NCBI

23 

Li Z, Zhou Y, Tu B, Bu Y, Liu A and Kong J: Long noncoding RNA MALAT1 affects the efficacy of radiotherapy for esophageal squamous cell carcinoma by regulating Cks1 expression. J Oral Pathol Med. 46:583–590. 2017. View Article : Google Scholar : PubMed/NCBI

24 

Xu L, Fan S, Zhao J, Zhou P, Chu S, Luo J, Wen Q, Chen L, Wen S, Wang L and Shi L: Increased expression of Cks1 protein is associated with lymph node metastasis and poor prognosis in nasopharyngeal carcinoma. Diagn Pathol. 12:22017. View Article : Google Scholar : PubMed/NCBI

25 

Wang D, Zhi T, Xu X, Bao Z, Fan L, Li Z, Ji J and Liu N: MicroRNA-936 induces cell cycle arrest and inhibits glioma cell proliferation by targeting CKS1. Am J Cancer Res. 7:2131–2143. 2017.PubMed/NCBI

26 

Kang MA, Kim JT, Kim JH, Kim SY, Kim YH, Yeom YI, Lee Y and Lee HG: Upregulation of the cycline kinase subunit CKS2 increases cell proliferation rate in gastric cancer. J Cancer Res Clin Oncol. 135:761–769. 2009. View Article : Google Scholar : PubMed/NCBI

27 

Ji X, Xue Y, Wu Y, Feng F and Gao X: High-expressed CKS2 is associated with hepatocellular carcinoma cell proliferation through down-regulating PTEN. Pathol Res Pract. 214:436–441. 2018. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

June 2019
Volume 19 Issue 6

Print ISSN: 1791-2997
Online ISSN:1791-3004

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Huang, N., Wu, Z., Hong, H., Wang, X., Yang, F., & Li, H. (2019). Overexpression of CKS2 is associated with a poor prognosis and promotes cell proliferation and invasion in breast cancer. Molecular Medicine Reports, 19, 4761-4769. https://doi.org/10.3892/mmr.2019.10134
MLA
Huang, N., Wu, Z., Hong, H., Wang, X., Yang, F., Li, H."Overexpression of CKS2 is associated with a poor prognosis and promotes cell proliferation and invasion in breast cancer". Molecular Medicine Reports 19.6 (2019): 4761-4769.
Chicago
Huang, N., Wu, Z., Hong, H., Wang, X., Yang, F., Li, H."Overexpression of CKS2 is associated with a poor prognosis and promotes cell proliferation and invasion in breast cancer". Molecular Medicine Reports 19, no. 6 (2019): 4761-4769. https://doi.org/10.3892/mmr.2019.10134